Dernières nouvelles pour Veracyte (NASDAQ:VCYT) Stock

Veracyte

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Veracyte Inc

On Friday, Cathie Wood-led Ark Invest made several significant trades. The most prominent among these involved the buying and selling of shares in Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>), Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), and UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>).
The NTLA Trade: Ark Invest&#8217;s ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund purchased 65,958 shares of Intellia Therapeutics. The shares were bought at a closing price of $8.31, making the total value of the trade approximately $548,136.78. This move comes amidst a 1.59% increase in NTLA&#8217;s stock price.
The META Trade: The ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) fund sold 1,255 shares of Meta Platforms at a closing price of $547.27. The total value of this sale was approximately $686,324.85. This trade was executed as META&#8217;s stock price saw a 2.65% increase.
The VCYT Trade: Ark Invest&#8217;s ARKK fund sold 66,135 shares of Veracyte. The shares were sold at a closing price of $32.23, making the total value of the trade approximately $2,131,151.05. This sale was made as VCYT&#8217;s stock price experienced a slight increase of 0.28%.
The SYM Trade: ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) fund bought 8,140 shares of Symbotic at a closing price of $21.93. The total value of this purchase was approximately $178,410.20. This purchase was made despite SYM&#8217;s stock price seeing a decrease of 0.59%.
The BIDU Trade: The ARKQ fund also bought 925 shares of Baidu at a closing price of $90.74. The total value of this purchase was approximately $83,934.50. This trade was executed as BIDU&#8217;s stock price saw a 1.39% increase.
The PATH Trade: Ark&#8217;s ARKW fund sold 984 shares of UiPath at a closing price of $11.59. The total value of this sale was approximately $11,402.56. This sale was made as PATH&#8217;s stock price experienced a 2.39% increase.
Read Next:
<ul>
<li><a href="https://benzinga.com/markets/equities/25/04/45001882/jim-cramer-stays-bullish-on-data-centers-says-if-trump-tariffs-eases-these-ai-stocks-will-fly-ag">Jim Cramer Stays Bullish On Data Centers, Says If Trump Tariffs Eases, These AI Stocks &#8216;Will Fly Again&#8217; Despite Wall Street Doubts</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

News

Markets

Tech

ETFs

ARKK

ARKQ

BIDU

NTLA

PATH

VCYT

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms

Veracyte Launches Decipher Prostate Metastatic Test, First Medicare-Covered Genomic Classifier For Advanced Prostate Cancer

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54241486&amp;newsitemid=20250422501694&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=14ab75ff8f2393b4488c836f365cf578">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented include new data from the use of the Decipher tests in clinical trials as well as insights into these cancers' underlying biology, which researchers derived through use of the whole-transcriptome-based Decipher GRID (Genomic Resource for Intelligent Discovery) research tool.

Veracyte Says At Least 18 Abstracts Focused On Decipher Prostate And Decipher Bladder Genomic Classifiers Will Be Presented At AUA 2025

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=bcb97a0a3c8892614f1297db580584e5">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) Program <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fseer.cancer.gov%2Fdata%2Fspecialized%2Favailable-databases%2Fdecipher-prostate-gc-request%2F&amp;esheet=54240820&amp;newsitemid=20250420178680&amp;lan=en-US&amp;anchor=just+released&amp;index=2&amp;md5=85917c7b4d1ecea2f5d8dfbbb5a0ff09">just released</a>. This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors.
 &nbsp;

Veracyte Says Data From Decipher Prostate Genomic Classifier Are Linked to Real-World Data in NCI's SEER Specialized Database Release

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and lowers the price target from $45 to $37.

Price Target

Analyst Ratings

Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $37

Stephens &amp; Co. analyst Mason Carrico reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Overweight and maintains $45 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Veracyte, Maintains $45 Price Target

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54228724&amp;newsitemid=20250325940531&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=fe7af866369bc9f5574b73433104b6e6">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based blood testing and earlier compared to standard imaging. The findings, from the large, independent, multicenter, interventional <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04138628&amp;esheet=54228724&amp;newsitemid=20250325940531&amp;lan=en-US&amp;anchor=TOMBOLA+trial&amp;index=2&amp;md5=99d285c1773d1c69fbd4f75c2b63055c">TOMBOLA trial</a> (NCT04138628), were shared in an oral presentation at the 40th Annual European Association of Urology Congress (EAU25) in Madrid by Iver Nordentoft, Ph.D., Aarhus University (Abstract A0162: &quot;Comparison of ctDNA detection methods for monitoring minimal residual disease in patients with bladder cancer: Insights from the TOMBOLA Trial&quot;).
The new study involved 100 patients enrolled in the TOMBOLA trial who had MIBC and were undergoing standard-of-care neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Their blood samples were evaluated for circulating tumor DNA (ctDNA) using both ddPCR-based and Veracyte&#39;s WGS-based MRD testing platform to detect disease recurrence. Patients also underwent imaging. At the 6-month milestone, in comparison to ddPCR, the Veracyte MRD testing platform had an equivalent and outstanding negative predictive value (95.9% Veracyte MRD vs. 96.2% ddPCR) for cancer recurrence, while having a higher specificity (88% Veracyte MRD vs. 62% ddPCR). Longer follow-up is required to determine the clinical impact of these results. The findings also showed that the Veracyte MRD testing platform detected cancer recurrence a median of 93 days sooner than imaging. In the ongoing trial, ctDNA-positive patients are treated with immunotherapy and followed for clinical response.
&quot;Up to half of patients with muscle-invasive bladder cancer experience recurrence within two years of initial treatment, and using ctDNA status to guide oncological treatment would spare some patients from unnecessary treatments,&quot; said Lars Dyrskj&oslash;t Andersen, Ph.D., professor in the Department of Clinical Medicine and Department of Molecular Medicine at Aarhus University in Denmark and principal investigator of the TOMBOLA trial. &quot;ctDNA testing using ddPCR has demonstrated promise for MRD detection, but it has inherent limitations that may impede its clinical use, particularly on a large scale. Our findings show that Veracyte&#39;s whole-genome sequencing approach to MRD testing demonstrates high accuracy and may improve overall clinical utility, compared to ddPCR.&quot;
Veracyte&#39;s MRD testing platform utilizes a combination of whole-genome sequencing and artificial intelligence (AI) to provide fast and accurate detection of residual cancer in a patient&#39;s blood sample. This approach requires less blood and offers faster results, compared to ctDNA testing that uses bespoke panels, enabling earlier detection and improved outcomes. Veracyte&#39;s MRD testing platform characterizes the complete set of cancer mutations in the tumor tissue sample and blood to establish a patient-specific, landmark genomic signature. It then uses whole-genome sequencing and AI to detect that signature in subsequent blood samples, indicating that cancer is present, and to track tumor progression throughout the patient&#39;s treatment and follow-up care. Veracyte plans to launch its first MRD test in muscle-invasive bladder cancer in the first half of 2026, with other cancer indications to follow.
&quot;The new data presented at EAU25 reinforce the power of the Veracyte Diagnostics Platform, which is at the core of all of our tests and will now enable us to expand into MRD testing in a clinically meaningful way,&quot; said Philip Febbo, M.D., Veracyte&#39;s chief scientific officer and chief medical officer. &quot;With our first MRD test in muscle-invasive bladder cancer, we are excited to expand our test offerings along the care continuum in urologic cancers where our Decipher tests are widely used and trusted by clinicians to help guide prognosis and treatment decisions.&quot;

Biotech

General

Veracyte To Present New Data Showing That Its Whole-Genome Sequencing-Based Platform For Minimal Residual Disease Testing Detected Cancer In Patients Treated For Muscle-Invasive Bladder Cancer With More Accuracy Than ddPCR-Based Blood Testing And Earlier Compared To Standard Imaging

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.2, a high estimate of $51.00, and a low estimate of $45.00. Witnessing a positive shift, the current average has risen by 3.66% from the previous average price target of $46.50.
<img src="https://www.benzinga.com/files/images/story/2025/1742497260_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Veracyte among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Veracyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Veracyte's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veracyte's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veracyte analyst ratings.</a>
<h2>Discovering Veracyte: A Closer Look</h2>
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
<h3>Veracyte's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Veracyte's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 20.81%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Veracyte's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.31%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.43% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Veracyte: What You Need To Know

Craig-Hallum analyst John Wilkin initiates coverage on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy rating and announces Price Target of $45.

Initiation

Craig-Hallum Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $45

Veracyte Plans To Present Multiple Abstracts At EAU25 Demonstrating Clinical Performance And Utility Of Its Decipher Tests In Prostate And Bladder Cancer

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Health Care

MYGN

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

5 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Veracyte, revealing an average target of $46.6, a high estimate of $51.00, and a low estimate of $37.00. Witnessing a positive shift, the current average has risen by 4.02% from the previous average price target of $44.80.
<img src="https://www.benzinga.com/files/images/story/2025/1740510024_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veracyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Veracyte. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Veracyte's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Veracyte's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veracyte analyst ratings.</a>
<h2>Get to Know Veracyte Better</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>A Deep Dive into Veracyte's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Veracyte displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 28.58%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 13.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE excels beyond industry benchmarks, reaching 1.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA stands out, surpassing industry averages. With an impressive ROA of 1.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Veracyte's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts

On Monday, Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported adjusted earnings of 36 cents. That&#8217;s up from 21 cents a year ago, beating the <a href="https://www.benzinga.com/pressreleases/25/02/b43925680/veracyte-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of 11 cents</a>.
The global diagnostic company reported sales of $118.6 million, up from $98.2 million a year ago. It beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $116.77 million</a>.
Testing revenue was $112.2 million, an increase of 24% year over year, driven by the strong performance of Decipher and Afirma tests. Total volume increased by 22% to 41,271 tests and testing volume by 25% to 39,107 tests.
Veracyte is evaluating its ownership and operations of its Marseille, France-based subsidiary, Veracyte SAS. The company's activities include its immune-oncology biopharma business, contract development and manufacturing, and support for its IVD development and manufacturing.&nbsp;
Veracyte recently notified Veracyte SAS that, as its sole shareholder, it is considering no longer funding the French entity. Accordingly, Veracyte SAS will engage with its works council over the next few months, as required by French law.
Seeking external buyer(s) for a potential divestiture of all or part of the French entity's activities is an option that is actively being explored.
William Blair analyst Andrew Brackmann writes, &#8220;While this adds a bit of uncertainty about the total company revenue and margins, we think walking away (or selling) could be a long-term positive.&#8221;
The analyst says the French subsidiary earns about $4 million in revenue each quarter but has $7 million in fixed costs, leading to a $5 million operating loss. Selling the unit or filing for bankruptcy could help Veracyte reduce costs.
Guidance: The company expects 2025 testing revenue of $470 million to $480 million, or 12% to 15% year-over-year growth.
The guidance implies testing revenue growth of 14% to 16%, adjusted for the impact of the paused Envisia test.
Given the number of variables impacting its Marseille, France operations, the company is not providing total revenue guidance now. It expects to provide its total revenue outlook for 2025 once there is more clarity on the timing and impact of the process underway.
The company also expects its adjusted EBITDA margin to be approximately 21.6% in 2025, compared to 20.6% in 2024.
Price Action: VCYT stock is down 2.90% at $38.23 during the premarket session on last check Tuesday.

Earnings

Guidance

Movers

Trading Ideas

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

UBS analyst Lu Li maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $46 to $49.

UBS Maintains Buy on Veracyte, Raises Price Target to $49

Guggenheim analyst Subbu Nambi reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and maintains $45 price target.

Guggenheim Reiterates Buy on Veracyte, Maintains $45 Price Target

Needham analyst Mike Matson reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and maintains $51 price target.

Needham Reiterates Buy on Veracyte, Maintains $51 Price Target

WIIM

Veracyte shares are trading lower. The company reported Q4 financial results.

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.11 by 227.27 percent. This is a 620 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $118.600 million which beat the analyst consensus estimate of $116.765 million by 1.57 percent. This is a 20.78 percent increase over sales of $98.199 million the same period last year.

Earnings Beats

Veracyte Q4 2024 Adj. EPS $0.36 Beats $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate

Veracyte Sees FY25 Testing Revenue $470M-$480M.

<h3>Companies Reporting Before The Bell</h3>
• Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $416.02 million. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $110.85 million. 
• Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) is projected to report earnings for its fourth quarter. 
• Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $645.84 million. 
• BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $127.72 million. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is expected to report quarterly earnings at $4.95 per share on revenue of $1.48 billion. 
• Gran Tierra Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GTE#AMEX">GTE</a>) is projected to report earnings for its fourth quarter. 
• Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $1.08 billion. 
• Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $2.96 billion. 
• Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) is likely to report quarterly earnings at $2.90 per share on revenue of $2.77 billion. 
• Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $1.03 billion. 
• Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $1.52 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $6.46 million. 
• Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $1.01 billion. 
<h3>Companies Reporting After The Bell</h3>
• DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) is likely to report quarterly loss at $0.29 per share on revenue of $140.50 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $559.19 million. 
• Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $99.87 million. 
• Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $78.20 million. 
• Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $159.89 million. 
• Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $281.61 million. 
• Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $469.68 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is likely to report quarterly loss at $0.75 per share on revenue of $331.06 million. 
• Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $1.39 billion. 
• Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $91.03 million. 
• Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) is likely to report quarterly loss at $0.27 per share on revenue of $130.25 million. 
• BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) is likely to report quarterly earnings at $0.81 per share on revenue of $720.47 million. 
• SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $684.39 million. 
• ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $6.77 billion. 
• Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.03 million. 
• Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $101.15 million. 
• EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $133.83 million. 
• Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) is projected to report quarterly loss at $0.29 per share on revenue of $105.90 million. 
• Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $116.68 million. 
• Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $1.59 billion. 
• Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $1.35 billion. 
• Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $1.69 billion. 
• HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $73.55 million. 
• Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $213.34 million. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $326.77 million. 
• Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) is likely to report quarterly loss at $0.19 per share on revenue of $885.10 million. 
• Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $182.09 million. 
• JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $488.74 million. 
• ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $274.56 million. 
• Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is estimated to report quarterly loss at $1.09 per share on revenue of $58.34 million. 
• Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $441.87 million. 
• Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $53.10 million. 
• Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) is projected to report quarterly loss at $0.06 per share on revenue of $19.03 million. 
• Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is projected to report quarterly loss at $0.15 per share on revenue of $200.55 million. 
• Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.35 per share on revenue of $278.36 million. 
• Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $175.99 million. 
• Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) is likely to report quarterly earnings at $2.63 per share on revenue of $424.40 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report earnings for its fourth quarter. 
• Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $114.99 million. 
• LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $42.81 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.19 billion. 
• Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $155.23 million. 
• MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $289.38 million. 
• SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is projected to report quarterly loss at $0.14 per share on revenue of $46.89 million. 
• Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $83.69 million. 
• Tortoise Capital Series Trust Tortoise Power and Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPZ#NYSE">TPZ</a>) is expected to report earnings for its fourth quarter. 
• Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is likely to report quarterly loss at $0.48 per share on revenue of $174.58 million. 
• Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $311.66 million. 
• Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) is projected to report quarterly earnings at $4.22 per share on revenue of $1.18 billion. 
• Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) is expected to report earnings for its fourth quarter. 
• V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.10 billion. 
• Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $66.81 million. 
• GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.98 billion. 
• Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $171.47 million. 
• Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) is estimated to report quarterly earnings at $1.88 per share on revenue of $1.29 billion. 
• Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is expected to report quarterly loss at $0.44 per share on revenue of $4.54 billion. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $43.47 million. 
• KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $2.00 billion. 
• Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $220.06 million. 
• Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is likely to report quarterly earnings at $3.58 per share on revenue of $3.51 billion. 
• Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $324.82 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

AESI

AORT

APLE

AROC

AZUL

BCRX

BOOM

BRDG

BWXT

BYON

CHGG

CIVI

CLNE

CNNE

CRGO

CTRA

CWEN

EVER

FANG

FARO

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HLIO

HSTM

ISPO

JBTM

KSPI

LINC

MODG

NTST

NVTS

OPAD

PLOW

PRIM

RIOT

SBAC

SIBN

SMMT

TCOM

TREX

UCTT

VNOM

WLKP

Earnings Scheduled For February 24, 2025

Press Releases

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte to Participate in Upcoming Investor Conferences

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Comments

Veracyte

Actualités

Dernières nouvelles pour Veracyte (NASDAQ:VCYT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL